Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00459
|
|||||
| Drug Name |
Fluoxetine
|
|||||
| Synonyms |
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Animex-On; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetina [INN-Spanish]; Fluoxetina [Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetine (USAN/INN); Fluoxetine Hcl; Fluoxetine [USAN:INN:BAN]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluval; Fontex; Lilly-110140; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Portal; Prozac (TN); Prozac Weekly; Pulvules; Reconcile; Reneuron
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Depression [ICD11: 6A8Z] | Approved | [1] | |||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H18F3NO
|
|||||
| Canonical SMILES |
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
|
|||||
| InChIKey |
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 54910-89-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 309.33 | Topological Polar Surface Area | 21.3 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11341994
, 11362177
, 11364573
, 11367135
, 11369697
, 11372694
, 11374305
, 11377859
, 11466539
, 11467659
, 11485551
, 11486118
, 11487579
, 11489474
, 11491463
, 11492428
, 11495493
, 143844
, 14874184
, 26751973
, 29222521
, 3249391
, 3719648
, 46507902
, 47365860
, 47515964
, 47515965
, 47589652
, 47662955
, 47960412
, 48111113
, 48259912
, 48259913
, 48416026
, 49698967
, 49833486
, 49880992
, 50104648
, 50319599
, 5367839
, 53787367
, 56312230
, 56312679
, 56312978
, 56313632
, 57321770
, 7847392
, 7979254
, 8152157
, 841244
|
|||||
| ChEBI ID |
ChEBI:5118
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fluoxetine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.